MedTrace Logo

Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases

NCT06483672 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2024-07-03

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if furmonertinib plus anlotinib works to treat participants with lung adenocarcinoma with EGFR mutations and brain metastases. It will also learn about the safety of furmonertinib plus anlotinib. The main questions it aims to answer are:

* Does furmonertinib plus anlotinib increase the number of participants who has a significant tumor shrinkage?
* What medical problems do participants have when taking furmonertinib plus anlotinib? Researchers will evaluate the safety and efficacy of furmonertinib plus anlotinib.

Participants will:

* Take furmonertinib(every day) and anlotinib(two weeks on and one week off)
* Visit the clinic once every 3 weeks for checkups and tests.
* Keep a diary of their symptoms.

Conditions

  • Adenocarcinoma of Lung Metastatic to Brain

Interventions

DRUG

Furmonertinib

Furmonertinib 80mg, once daily, orally

DRUG

Anlotinib

Anlotinib 12mg, once daily (days 1-14, 21 days per cycle), orally

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Sheng Yang, Doctor · Cancer Hospital, CAMS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-31
Primary Completion
2025-12-31
Completion
2027-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06483672 on ClinicalTrials.gov